Metronidazole

Name: Metronidazole
Brand: MedChemExpress
SKU: HY-B0318
Rating: 5.0 (65 reviews)

Cat. No.: HY-B0318 Purity: 99.96%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

Metronidazole is an orally active nitroimidazole antibiotic. Metronidazole can cross blood brain barrier. Metronidazole can be used for the research of anaerobic infections.

For research use only. We do not sell to patients.

CAS No. : 443-48-1

Size	Stock	Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	In-stock	Estimated Time of Arrival: December 31
Solid
500 mg	In-stock	Estimated Time of Arrival: December 31
5 g	In-stock	Estimated Time of Arrival: December 31
10 g	In-stock	Estimated Time of Arrival: December 31
25 g	In-stock	Estimated Time of Arrival: December 31
50 g	In-stock	Estimated Time of Arrival: December 31
100 g	In-stock	Estimated Time of Arrival: December 31
> 100 g	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 65 publication(s) in Google Scholar

Other Forms of Metronidazole:

65 Publications Citing Use of MCE Metronidazole

ELISA

In Vivo Imaging

PK/PD Analysis

Bio/Physico-chemical Assay

RT-PCR

: Metronidazole purchased from MedChemExpress. Usage Cited in: Gut Microbes. 2025 Dec;17(1):2545434. [Abstract]; Western blot analysis of METTL3 and YTHDF2 protein expression from the CON and ABX (Ampicillin (1 g/L), Neomycin (1 g/L), Metronidazole (1 g/L), and vancomycin (0.5 g/L); drinking water from 6 to 12 weeks) mice (n = 3/group).

: Metronidazole purchased from MedChemExpress. Usage Cited in: Gut Microbes. 2025 Dec;17(1):2545434. [Abstract]; RT-qPCR analysis of METTL3 and YTHDF2 protein expression from the CON and ABX (Ampicillin (1 g/L), Neomycin (1 g/L), Metronidazole (1 g/L), and vancomycin (0.5 g/L); drinking water from 6 to 12 weeks) mice (n = 3/group).

: Metronidazole purchased from MedChemExpress. Usage Cited in: J Exp Med. 2026 Mar 2;223(3):e20241287. [Abstract]; The number and frequency of MAIT cells in the ear pinnae and lungs of mice at 8 wk old following treatment with Metronidazole (30 mg/kg/day; oral gavage; from 2 to 4 weeks).

: Metronidazole purchased from MedChemExpress. Usage Cited in: J Neuroinflammation. 2025 Nov 4;22(1):259. [Abstract]; Sufficiently enhanced susceptibility to JE by ampicillin (A) and/or Metronidazole (M) (1 g/L; drinking water; for 21 days) treatment in C57BL/6 mice.

: Metronidazole purchased from MedChemExpress. Usage Cited in: Gut Microbes. 2023 Dec;15(2):2249143. [Abstract]; Targeted metabolomics analysis of gut microbial metabolites (AA, PA, and BA) in colon contents (feces) and serum from mice with or without ABX treatment (n = 6 per group). ABX: an antibiotic cocktail of 0.5 g/L Vancomycin, 1 g/L Metronidazole,1 g/L Neomycin and 1 g/L Ampicillin

: Metronidazole purchased from MedChemExpress. Usage Cited in: Gut Microbes. 2023 Dec;15(2):2282790. [Abstract]; Depletion of CD8+ T cells in ABX-treated B16-F0 tumor-bearing mice dampened the antitumor effect of butyrate combined with anti-PD-1 (Figure 4b–e). Decreased serum IFN-γ and TNF-α production during the depletion of CD8+ T cells was also observed. ABX：an antibiotic cocktail of 0.5 g/L Vancomycin, 1 g/L Metronidazole, 1 g/L Neomycin and 1 g/L Ampicillin.

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Parasite Isoform Specific Products:

View All Isoforms

Amebae Coccidia Leishmania Mite Plasmodium Toxoplasma Trypanosoma Schistosome

View All Antibiotic Isoform Specific Products:

View All Isoforms

Aminoglycoside Glycopeptide Lipopeptide Macrolide Oxazolidinone Quinolone Tetracycline β-lactam

Biological Activity
Purity & Documentation
References
Customer Review

Description

Metronidazole is an orally active nitroimidazole antibiotic. Metronidazole can cross blood brain barrier. Metronidazole can be used for the research of anaerobic infections^[1]^[2]^[3]^[4].

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	223.78 μg/mL Compound: MTZ	Cytotoxicity against human A549 cells after 24 hrs by MTT assay Cytotoxicity against human A549 cells after 24 hrs by MTT assay	[PMID: 30554970]
A549	IC₅₀	> 100 μM Compound: Mtz	Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 27598233]
BEAS-2B	IC₅₀	2.24 mM Compound: MTZ	Cytotoxicity against human BEAS-2B cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against human BEAS-2B cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 33231455]
CHO	IC₅₀	177.9 μM Compound: metronidazole	Inhibition of Cav1.2 current measured using QPatch automatic path clamp system in CHO cells expressing Cav1.2, beta-2 and alpha-2/delta-1 subunits Inhibition of Cav1.2 current measured using QPatch automatic path clamp system in CHO cells expressing Cav1.2, beta-2 and alpha-2/delta-1 subunits	[PMID: 23812503]
CHO	IC₅₀	280 μM Compound: 18; MNZ	Cytotoxicity against CHO cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against CHO cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 27597415]
CHO	IC₅₀	> 400 μM Compound: 18; MNZ	Cytotoxicity against CHO cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against CHO cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 27597415]
CHO-AA8	IC₅₀	23 mM Compound: 5	Concentration required to reduce AA8 cell numbers to 50% of controls in a growth inhibition microassay Concentration required to reduce AA8 cell numbers to 50% of controls in a growth inhibition microassay	[PMID: 8308864]
CHO-K1	IC₅₀	2.92 mM Compound: MTZ	Cytotoxicity against CHO-K1 cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against CHO-K1 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 33231455]
Epithelial cell	IC₅₀	> 100 μM Compound: Metronidazole	Cytotoxicity against human kidney epithelial cells after 44 hrs by MTT assay Cytotoxicity against human kidney epithelial cells after 44 hrs by MTT assay	[PMID: 18068273]
Epithelial cell	IC₅₀	> 100 μM Compound: Metronidazole	Cytotoxicity against human kidney epithelial cells after 44 hrs by MTT assay Cytotoxicity against human kidney epithelial cells after 44 hrs by MTT assay	[PMID: 18378360]
Epithelial cell	IC₅₀	> 100 μM Compound: metronidazole	Cytotoxicity against human kidney epithelial cells after 44 hrs by MTT assay Cytotoxicity against human kidney epithelial cells after 44 hrs by MTT assay	[PMID: 18187238]
H9c2	IC₅₀	> 116 μM Compound: Metronidazole	Toxicity in rat H9c2 cells after 48 hrs by MTT assay Toxicity in rat H9c2 cells after 48 hrs by MTT assay	[PMID: 19589625]
H9c2	IC₅₀	> 200 μM Compound: MNZ	Cytotoxicity against rat H9c2 cells assessed as cell viability after 48 hrs by MTT assay Cytotoxicity against rat H9c2 cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 21715066]
HEK293	CC₅₀	> 100 μM Compound: 1	Cytotoxicity against HEK293 cells assessed as cell growth inhibition after 24 hrs by resazurin assay Cytotoxicity against HEK293 cells assessed as cell growth inhibition after 24 hrs by resazurin assay	[PMID: 27236016]
HEK293	IC₅₀	> 100 μM Compound: Metronidazole	Cytotoxicity against HEK cells after 44 hrs by MTT assay Cytotoxicity against HEK cells after 44 hrs by MTT assay	[PMID: 18384916]
HT-29	IC₅₀	278.08 μg/mL Compound: MTZ	Cytotoxicity against human HT-29 cells after 24 hrs by MTT assay Cytotoxicity against human HT-29 cells after 24 hrs by MTT assay	[PMID: 30554970]
HeLa	CC₅₀	285.7 μM Compound: MTZ	Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 38461555]
HeLa	CC₅₀	666.2 μM Compound: MTZ	Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 38461555]
HeLa	EC₅₀	> 1000 μg/mL Compound: Metronidazole	Cytotoxicity against human HeLa cells by MTT assay Cytotoxicity against human HeLa cells by MTT assay	[PMID: 22846917]
HeLa	IC₅₀	> 1000 μg/mL Compound: MTZ	Cytotoxicity against human HeLa cells after 24 hrs by MTT assay Cytotoxicity against human HeLa cells after 24 hrs by MTT assay	[PMID: 24727243]
HeLa	IC₅₀	> 1000 μg/mL Compound: MTZ	Cytotoxicity against human HeLa cells Cytotoxicity against human HeLa cells	[PMID: 24900434]
HeLa	IC₅₀	> 5000 μM Compound: MTZ	Cytotoxicity against human HeLa cells after 24 hrs by MTT assay Cytotoxicity against human HeLa cells after 24 hrs by MTT assay	[PMID: 27643640]
HeLa	IC₅₀	> 5000 μM Compound: MTZ	Cytotoxicity against human HeLa cells after 24 hrs by MTT assay Cytotoxicity against human HeLa cells after 24 hrs by MTT assay	[PMID: 29216562]
HepG2	CC₅₀	> 100 μM Compound: 1	Cytotoxicity against human HepG2 cells assessed as cell growth inhibition after 24 hrs by resazurin assay Cytotoxicity against human HepG2 cells assessed as cell growth inhibition after 24 hrs by resazurin assay	[PMID: 27236016]
HepG2	IC₅₀	> 100 μM Compound: MNZ	Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 22236470]
HepG2	IC₅₀	> 100 μM Compound: MNZ	Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 23644202]
HepG2	IC₅₀	> 100 μM Compound: MNZ, Metronidazole	Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 22658085]
HepG2	IC₅₀	> 100 μM Compound: MNZ, Metronidazole	Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 22840694]
KB	IC₅₀	> 100 μM Compound: MNZ, metronidazole	Cytotoxicity against human KB cells after 44 hrs by MTT assay Cytotoxicity against human KB cells after 44 hrs by MTT assay	[PMID: 18222017]
KB	IC₅₀	> 100 μM Compound: metronidazole (MNZ)	Cytotoxicity against human KB cells after 44 hrs by MTT assay Cytotoxicity against human KB cells after 44 hrs by MTT assay	[PMID: 17513021]
MCF7	IC₅₀	347.96 μg/mL Compound: MTZ	Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay	[PMID: 30554970]
MCF7	IC₅₀	> 100 μM Compound: Metronidazole	Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 20696501]
MCF7	IC₅₀	> 100 μM Compound: Metronidazole	Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 20961670]
MCF7	IC₅₀	> 100 μM Compound: metronidazole	Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 21377771]
MCF7	IC₅₀	> 250 μM Compound: 1, MNZ	Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 22832309]
MCF7	IC₅₀	> 250 μM Compound: MNZ	Cytotoxicity against Homo sapiens (human) MCF-7 cells assessed as decrease in number of viable cells after 48 hr by MTT assay Cytotoxicity against Homo sapiens (human) MCF-7 cells assessed as decrease in number of viable cells after 48 hr by MTT assay	10.1007/s00044-012-0070-6
MCF7	IC₅₀	> 250 μM Compound: MNZ	Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 22444681]
MCF7	IC₅₀	> 250 μM Compound: Metronidazole	Cytotoxicity against Homo sapiens (human) MCF7 cells after 48 hr by MTT assay Cytotoxicity against Homo sapiens (human) MCF7 cells after 48 hr by MTT assay	10.1007/s00044-012-0107-x
MCF7	IC₅₀	> 250 μM Compound: Metronidazole	Cytotoxicity against human MCF7 cells assessed as cell viability after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 22309914]
MDCK	CC₅₀	68 μM Compound: Met	Cytotoxicity against MDCK cells after 72 hrs by MTT assay Cytotoxicity against MDCK cells after 72 hrs by MTT assay	[PMID: 19208443]
Splenocyte	IC₅₀	5.4 μM Compound: Mtz	Cytotoxicity against BALB/c mouse splenocytes assessed as [3H]-thymidine incorporation after 24 hrs by beta-radiation counting analysis relative to control Cytotoxicity against BALB/c mouse splenocytes assessed as [3H]-thymidine incorporation after 24 hrs by beta-radiation counting analysis relative to control	[PMID: 24530492]
THP-1	IC₅₀	> 1460 μM Compound: 5	Cytotoxicity against human THP1 cells after 72 hrs by propidium iodide-based flow cytometry Cytotoxicity against human THP1 cells after 72 hrs by propidium iodide-based flow cytometry	[PMID: 18590939]
THP-1	IC₅₀	> 500 μM Compound: Metronidazole	Cytotoxicity against human THP1 cells after 72 hrs by propidium iodide staining-based flow cytometry Cytotoxicity against human THP1 cells after 72 hrs by propidium iodide staining-based flow cytometry	[PMID: 19748781]
Vero	CC₅₀	367 μM Compound: Metronidazole	Cytotoxicity against African green monkey Vero cells after 48 hrs by MTT assay Cytotoxicity against African green monkey Vero cells after 48 hrs by MTT assay	[PMID: 25801157]
Vero	CC₅₀	387 μM Compound: MNZ	Cytotoxicity against African green monkey Vero cells assessed as cell viability after 48 hrs by SRB assay Cytotoxicity against African green monkey Vero cells assessed as cell viability after 48 hrs by SRB assay	[PMID: 24529307]
Vero	CC₅₀	387 μM Compound: Metronidazole	Cytotoxicity against african green monkey Vero cells after 72 hrs by MTT assay Cytotoxicity against african green monkey Vero cells after 72 hrs by MTT assay	[PMID: 21397502]
Vero	CC₅₀	387 μM Compound: Metronidazole	Cytotoxicity against African green monkey Vero cells incubated for 24 to 48 hrs by SRB assay Cytotoxicity against African green monkey Vero cells incubated for 24 to 48 hrs by SRB assay	[PMID: 28645659]
Vero	CC₅₀	> 16 μg/mL Compound: metronidazole	Cytotoxicity against african green monkey Vero cells after 72 hrs by CellTiterGlo assay Cytotoxicity against african green monkey Vero cells after 72 hrs by CellTiterGlo assay	[PMID: 22691154]
Vero	CC₅₀	> 300 μM Compound: MTZ	Cytotoxicity against African green monkey Vero cells Cytotoxicity against African green monkey Vero cells	[PMID: 33556576]
Vero	CC₅₀	> 300 μM Compound: Metro	Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability incubated for 24 hrs by resazurin dye based fluorometric analysis Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability incubated for 24 hrs by resazurin dye based fluorometric analysis	[PMID: 37729094]
Vero	CC₅₀	> 600 μM Compound: MTZ	Cytotoxicity against African green monkey Vero cells assessed as inhibition of cell growth after 24 hrs by resazurin redox dye based fluorimetric microtiter method Cytotoxicity against African green monkey Vero cells assessed as inhibition of cell growth after 24 hrs by resazurin redox dye based fluorimetric microtiter method	[PMID: 25771033]
Vero	CC₅₀	> 600 μM Compound: Metronidazole	Cytotoxicity against african green monkey Vero cells assessed as inhibition of cell growth after 24 hrs by resazurin dye based fluorescence assay Cytotoxicity against african green monkey Vero cells assessed as inhibition of cell growth after 24 hrs by resazurin dye based fluorescence assay	[PMID: 27017556]
Vero	IC₅₀	> 100 μM Compound: MTZ	Cytotoxicity against african green monkey Vero cells assessed as cell viability after 48 hrs by WST-1 assay Cytotoxicity against african green monkey Vero cells assessed as cell viability after 48 hrs by WST-1 assay	[PMID: 23787289]

In Vitro

Metronidazole displays inhibitory activity towards anaerobic protozoa Trichomonas vaginalis, Entamoeba histolytica, Giardia lamblia, and Balantidium coli^[1].
Metronidazole (4-8 μg/mL) inhibits anaerobic bacteria and shows good bactericidal activity^[1].
Metronidazole (0.1 μg/mL-0.01 mg/mL; 12-96 h) induces granular formation and triggers apoptosis in Blastocystis sp^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Apoptosis Analysis^[2]

Cell Line:	Blastocystis sp. Cells
Concentration:	0.1 μg/mL-0.01 mg/mL
Incubation Time:	12, 24, 48, 60, 72, 84, 96 hours
Result:	Decreased cell diameter, as a hallmark of an apoptotic cell, and resulted cell shrinkage.

In Vivo

Metronidazole (135 mg/kg/d; p.o.; 28 d) can cross the blood brain barrier, and exhibits neurotoxicity under long term administration in rats^[3].
Metronidazole (1 g/L; p.o.; 4 weeks) results skeletal muscle atrophy and changes the expression of genes involved in the muscle peripheral circadian rhythm machinery and metabolic regulation^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Sprague-Dawley (SD) rats (200-220 g)^[3]
Dosage:	135 mg/kg
Administration:	Oral gavage; once daily; 28 days
Result:	Caused inflammatory markers increasing, including iNOS, eNOS, Bax and caspase 3 protein expressions increasing and caused oxidative stress damage in brain tissue, with MDA content rising.

Animal Model:	SPF C57Bl/6J mice (6-7 months old)^[4]
Dosage:	1 g/L
Administration:	Oral gavage; provided with drinking water for 4 weeks, changed twice weekly
Result:	Resulted the muscle core clock and effector genes Cry2, Ror-β, E4BP4, PP ARγ and adiponectin expression increasing. Decreased hind limb muscle weight and resulted in smaller fibers in the tibialis anterior muscle.

Molecular Weight

171.16

Formula

C₆H₉N₃O₃

CAS No.

443-48-1

Appearance

Solid

Color

White to off-white

SMILES

OCCN1C([N+]([O-])=O)=CN=C1C

Structure Classification

Initial Source

Microorganisms

Gram-negative and Gram-positive anaerobic

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, protect from light

*In solvent : -80°C, 1 year; -20°C, 6 months (protect from light)

Solvent & Solubility

In Vitro:

DMSO : 35 mg/mL (204.49 mM; Need ultrasonic and warming; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : 5 mg/mL (29.21 mM; ultrasonic and warming and heat to 60°C)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	5.8425 mL	29.2124 mL	58.4249 mL
5 mM	1.1685 mL	5.8425 mL	11.6850 mL
10 mM	0.5842 mL	2.9212 mL	5.8425 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months (protect from light). When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (12.15 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (12.15 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.08 mg/mL (12.15 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: PBS
Solubility: 12.5 mg/mL (73.03 mM); Clear solution; Need ultrasonic and warming and heat to 60°C

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

*In solvent : -80°C, 1 year; -20°C, 6 months (protect from light)

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.96%

Select Batch:

Data Sheet (282 KB) SDS (419 KB)

COA (253 KB) HNMR (239 KB) RP-HPLC (260 KB) MS (201 KB)

Handling Instructions (2659 KB)

References

[1]. Scully BE. Metronidazole. Med Clin North Am. 1988 May;72(3):613-21. [Content Brief]

[2]. Dhurga DB, et al. Granular Formation during Apoptosis in Blastocystis sp. Exposed to Metronidazole (MTZ). PLoS One. 2016 Jul 29;11(7):e0155390. [Content Brief]

[3]. Chaturvedi S, et al. Mechanistic exploration of quercetin against metronidazole induced neurotoxicity in rats: Possible role of nitric oxide isoforms and inflammatory cytokines. Neurotoxicology. 2020 Jul;79:1-10. [Content Brief]

[4]. Manickam R, et al. Metronidazole Causes Skeletal Muscle Atrophy and Modulates Muscle Chronometabolism. Int J Mol Sci. 2018 Aug 16;19(8):2418. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

H₂O / DMSO	1 mM	5.8425 mL	29.2124 mL	58.4249 mL	146.0622 mL
	5 mM	1.1685 mL	5.8425 mL	11.6850 mL	29.2124 mL
	10 mM	0.5842 mL	2.9212 mL	5.8425 mL	14.6062 mL
	15 mM	0.3895 mL	1.9475 mL	3.8950 mL	9.7375 mL
	20 mM	0.2921 mL	1.4606 mL	2.9212 mL	7.3031 mL
	25 mM	0.2337 mL	1.1685 mL	2.3370 mL	5.8425 mL
DMSO	30 mM	0.1947 mL	0.9737 mL	1.9475 mL	4.8687 mL
	40 mM	0.1461 mL	0.7303 mL	1.4606 mL	3.6516 mL
	50 mM	0.1168 mL	0.5842 mL	1.1685 mL	2.9212 mL
	60 mM	0.0974 mL	0.4869 mL	0.9737 mL	2.4344 mL
	80 mM	0.0730 mL	0.3652 mL	0.7303 mL	1.8258 mL
	100 mM	0.0584 mL	0.2921 mL	0.5842 mL	1.4606 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Metronidazole Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Please select a local distributor ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Product Name			Requested Quantity *
Applicant Name *			Salutation
Email Address *			Phone Number *
Department			Organization Name *
City			State
Country or Region *
Remarks

Product Name			Lot #
Applicant Name *			Email Address *
Phone Number			Department *
Organization Name *			Country or Region *
Remarks

Metronidazole

Customer Review

Other Forms of Metronidazole:

65 Publications Citing Use of MCE Metronidazole

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Parasite Isoform Specific Products:

View All Antibiotic Isoform Specific Products:

Biological Activity

Purity & Documentation

References

Customer Review

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Metronidazole Related Classifications

Keywords:

Your Recently Viewed Products:

Name
Email *

	Sorry, but the email address you supplied was invalid.

Metronidazole

Customer Review

Other Forms of Metronidazole:

Metronidazole Related Antibodies

65 Publications Citing Use of MCE Metronidazole

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Parasite Isoform Specific Products:

View All Antibiotic Isoform Specific Products:

Biological Activity

Purity & Documentation

References

Customer Review

Metronidazole Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Metronidazole Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report